Zynerba Pharmaceuticals appoints Richard Baron as vice president and chief financial officer
Synthetic cannabinoid specialist Zynerba Pharmaceuticals has appointed Richard Baron as vice president and chief financial officer.
He brings more than 30 years of experience in executive finance leadership in the sector. Prior to this appointment, he was senior vice president and chief financial officer of Globus Medical (NYSE: GMED), and has also been vice president, finance and chief financial officer of Avid Radiopharmaceuticals.
Armando Anido, chairman and chief executive of Zynerba, said: "Rick has an exemplary track record of successfully helping emerging companies grow to the next level through strategic financing. He will be a valued member of the Zynerba team as we rapidly approach clinical development of these novel transdermal synthetic cannabinoid candidates in the coming months and work to take the company to the next stage."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze